Investor Presentation

5 Investor presentation First six months of 2022 Sales growth of 16% driven by both operating units Reported geographic sales split for first half of 2022 Novo NordiskⓇ Reported therapy area sales and growth for first half of 2022 DKK billion Insulin GLP-1 Obesity care Rare disease Other diabetes Growth at CER DKK North America Operations International Operations billion Growth at CER 90 00 16% 45% -8% 84% 0% 50 10% 40 40 International Operations 30 12% 20 20 10 21% -5% 24% 75 60 60 45 10% ΙΟ -5% 50 30 NAO -18% 53% 24% 15 ΙΟ 60% NAO 102% IO 1% NAO -1% 41% 0 0 ΙΟ EMEA China ROW NAO Total¹ 1 GLP-1 Insulin Obesity care Rare disease Source: Quarterly company announcement 1 'Other diabetes' is included in Total IO: International Operations; EMEA: Europe, Middle East and Africa; China: Mainland China, Hong Kong and Taiwan; ROW: Rest of World; NAO: North America Operations Note: Unless otherwise specified, sales growth rates are at CER

View entire presentation